Curacyte AG

With Big Pharma content to sit on the sidelines and wait as biotech company valuations continue their fall, the M&A activity that does take place is likely to place a premium on hedging risk. And, say

Biopharmaceutical, medical device, and in vitro diagnostics start-up dealmaking from July through September 2008. Data from FDC-Windhover's Strategic Transactions. Amanda Micklus Financings Financing

In Vitro Diagnostics Alliances

Despite investors' pleas, most observers agree there are still far too many small, sub-critical biotech firms in Europe. Yet two late-2003 deals—CeNeS' acquisition of TheraSci, and Develogen's merger